TriSalus Life Sciences (TLSIW) Cash & Equivalents (2021 - 2026)

TriSalus Life Sciences has reported Cash & Equivalents for 6 years, with the latest figure at $56.6 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents rose 335.02% year-over-year to $56.6 million; the trailing twelve-month figure through Mar 2026 stood at $56.6 million (up 335.02% YoY), and the FY2025 full-year result was $20.4 million, up 139.75% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $56.6 million, up from $20.4 million in the prior quarter.
• The five-year high for Cash & Equivalents was $56.6 million in Q1 2026, with the low at $69182.0 in Q2 2022.
• Historically, Cash & Equivalents has averaged $13.9 million across 5 years, with a median of $11.5 million in 2023.
• The largest YoY upside for Cash & Equivalents was 15750.93% in 2024 against a maximum downside of 47.21% in 2024.
• TriSalus Life Sciences' Cash & Equivalents stood at $9.4 million in 2022, then increased by 25.1% to $11.8 million in 2023, then retreated by 27.61% to $8.5 million in 2024, then surged by 139.75% to $20.4 million in 2025, then surged by 176.69% to $56.6 million in 2026.
• The last three Cash & Equivalents figures came in at $56.6 million (Q1 2026), $20.4 million (Q4 2025), and $22.7 million (Q3 2025), per Business Quant data.